Pharma Stock (Company), Caplin Point Laboratories, will be in focus this week because its wholly owned subsidiary, Caplin Steriles Limited has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Phytonadione Injectable Emulsion USP, 10 mg/mL, Single Dose Vial.
Share Price Insight of Caplin Point Laboratories
On 22 April 2025, Caplin Point Laboratories opened at ₹1924.15 from its previous close of ₹1911.35. Throughout the trading day (22 April 2025), the price of the stock faced many ups and downs, with a single-day high of ₹1924.15, and it closed at ₹1890.15.
On 23 April, Caplin Point Laboratories opened at ₹1904.10 and moved to ₹1913.35. (At the time of writing)
What is the News?
According to IQVIA™ data, the U.S. market for Phytonadione Injectable Emulsion was valued at approximately $18.5 million for the 12 months ending February 2025. While the product’s market size is modest compared to blockbuster drugs, it is considered a valuable addition to Caplin’s U.S. portfolio due to its clinical importance and steady demand.
After approval from the USFDA, Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories (Pharma Stock), will launch its generic version of Vitamin K1 Injection, a widely used drug indicated for treating bleeding disorders caused by vitamin K deficiency.
Caplin Point Laboratories Share Performance for 5 Days, 1 Month, and 6 Months:
In the last 5 days, Caplin Point Laboratories has given a negative return of 2.60%, while in the last 1 month, it has delivered an 8.11% negative return. In 6 months, the stock price has moved up by 3.05%.
Shareholding Pattern of Caplin Point Laboratories
| Perticulars | June 2024 | Sep. 2024 | Dec. 2024 | March. 2025 |
| Promotors | 70.56% | 70.56% | 70.56% | 70.56% |
| FIIs | 3.38% | 3.71% | 4.86% | 5.73% |
| DIIs | 1.49% | 1.83% | 2.11% | 2.00% |
| Public | 24.59% | 23.93% | 22.48% | 21.72% |
About Caplin Point Laboratories
Caplin Point Laboratories is a pharmaceutical company that deals in manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other countries.
The company’s more than 65% of the drugs are on the WHO’s essential drug list.
Disclaimer: This article is intended solely for educational use. Information about the companies referenced may evolve over time. The securities mentioned serve as examples and should not be considered investment recommendations.